The publisher explores Astellas’s prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Snapshot
- Overview - Astellas is forecast to grow revenue until 2026, at which point flagship product Xtandi will face the loss of patent exclusivity.
- Key themes - [1] Minimal short-term losses due to termination of sales and distribution agreement for Symbicort as well as decreases in vaccine revenues will be offset by its growing products [2] Astellas’s growth will be determined by new launched and pipeline assets such as Xospata, Evrenzo, and Evenity.
- Xtandi forecast adjusted higher due to continued growth in prostate cancer
- Xospata forecast adjusted higher
- Celebrex forecast adjusted lower due to generic competition
- Sujanu forecast adjusted higher due to continued growth
- AT132 removed from forecast due to multiple patient deaths and clinical hold in ASPIRO trial.
- Xospata forecast adjusted higher due to Europe launch
- Evenity forecast adjusted higher due to launch results
- Padcev EU and ROW launches expedited
- Roxadustat name changed to Evrenzo
- AT132 launch added due to closing of Audentes acquisition.
- Xtandi revenue adjusted higher due to non-metastatic castration-resistant prostate cancer prescriptions exceeding forecast in the US
- Prograf forecast adjusted higher due to lower generic impact in the US
- Micardis forecast adjusted higher due to generic performance
- Roxadustat forecast adjusted for approval
- Symbicort forecast removed due to termination of sales and distribution agreement with KM Biologics
- Vaccines forecast adjusted lower due to company guidance.
- AmBisome forecast adjusted higher due to company guidance
- Celebrex forecast adjusted higher due to company guidance
- Cresemba forecast adjusted lower for future patent expiry
- Mycamine forecast adjusted higher due to company guidance
- Xtandi forecast adjusted higher due to prostate cancer and overactive bladder treatment approvals
- Xospata forecast adjusted higher due to launch results
- Myrbetriq forecast adjusted lower due to company guidance
- Vesicare forecast adjusted lower due to generic competition
- Prograf forecast adjusted higher due to company guidance and expansion of clinical adoption in China
- Evenity forecast adjusted higher due to launch results
- Enfortumab vedotin forecast added
- Fezolinetant forecast added.
Note: Product cover images may vary from those shown
Company Background
- Company Overview
- Key Metrics
- SWOT Analysis
- Key Drug & Company Information
- Company Comparison
- Pharma Insights Analysis
- Prescription Pharmaceuticals Sales Outlook
- Branded Drug Outlook
- Launch Profile Outlook
- Therapy Area Outlook
- Regional Sales Outlook
- Lifecycle Analysis
- Marketed & Pipeline Drugs
- Recent Events & Analyst Opinions
- Upcoming Catalysts
- Recent Insights
- Clinical Trial Snapshot
- Clinical Trials by Country
- Clinical Trials by Status and Phase
- Clinical Trials by Drug
Note: Product cover images may vary from those shown